Literature DB >> 7025303

Primary sclerosing cholangitis.

L F Williams, D J Schoetz.   

Abstract

In spite of an improved understanding of the etiology of primary sclerosing cholangitis, which supports the use of immunosuppressive therapy with steroids and azathioprine, these pharmacologic manipulations have not altered the ultimate outcome of the disease. Drainage remains the most accepted mode of therapy when possible. Recent advances in diagnosis with ERCP and treatment with transhepatic biliary drainage may change the time-honored surgical approach to this disease as these techniques become more widely available. Until then, however, proper surgical management depends upon a high index of suspicion at the time of laparotomy so that irrevocable damage to the biliary tree will not be done prior to the establishment of the correct diagnosis. Simple drainage of the biliary tree will provide symptomatic relief in some patients; unfortunately, most patients will succumb to progressive biliary cirrhosis or sepsis in spite of all treatment.

Entities:  

Mesh:

Year:  1981        PMID: 7025303     DOI: 10.1016/s0039-6109(16)42491-6

Source DB:  PubMed          Journal:  Surg Clin North Am        ISSN: 0039-6109            Impact factor:   2.741


  5 in total

1.  Primary sclerosing cholangitis in India.

Authors:  S K Acharya; S Vashisht; R K Tandon
Journal:  Gastroenterol Jpn       Date:  1989-02

2.  Pediatric primary sclerosing cholangitis.

Authors:  D A Johnson; E L Cattau; J E Hancock
Journal:  Dig Dis Sci       Date:  1986-07       Impact factor: 3.199

3.  Primary sclerosing cholangitis: results of an aggressive surgical approach.

Authors:  H A Pitt; H H Thompson; R K Tompkins; W P Longmire
Journal:  Ann Surg       Date:  1982-09       Impact factor: 12.969

4.  Expression of laminin in benign and malignant sclerosing lesions of extrahepatic bile ducts.

Authors:  C Haglund; P J Roberts; S Nordling
Journal:  J Clin Pathol       Date:  1989-09       Impact factor: 3.411

5.  Macroscopically-localized hepatic lesions in sclerosing cholangitis.

Authors:  V L Touquet
Journal:  J R Soc Med       Date:  1983-09       Impact factor: 18.000

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.